Benzinga
Benzinga
Benzinga
viernes, septiembre 11

Corbus Pharmaceuticals Holdings Inc

CRBPNASDAQ
Trade with Public
Trade with Public
$8.24
-0.62-7%
al cierre: Sep 10, 5:00 PM EST
$8.20
-0.04-0.49%
After hour: 4:16 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Corbus Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Corbus Pharmaceuticals (CRBP).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

10Buy
Consensus RatingBuy# Analysts10Avg. Consensus PT$43Upside to Avg. PT+418.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026OppenheimerJeff JonesPT CutOutperform$52→$48
Aug 7, 2026HC Wainwright & Co.Andres Y. MaldonadoPT CutBuy$40→$35
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $40 to $35.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $54 to $52.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $40 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved